Eikon Therapeutics, Inc. cotiza a 7.26 USD y tiene una capitalización bursátil de $393M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and …
| Periodo | 2026-08 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | $-1.63 | — | $-2.46 | $-26.23 |
| Estimado | $-1.46 | $-1.46 | $-1.22 | $-17.75 |
| Sorpresa | -11.6% | — | -101.6% | -47.8% |
| Métrica | EIKN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | — | -32.0% | — |
| Current Ratio | 6.34 | 2.84 | +3.50 |
| Debt / Equity | — | 0.28 | — |